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miR-196a Downregulation Increases the Expression
of Type I and III Collagens in Keloid Fibroblasts
Kazuya Kashiyama1,2, Norisato Mitsutake1,3, Michiko Matsuse1, Tomoo Ogi1,3, Vladimir A. Saenko4,
Kenta Ujifuku5, Atsushi Utani6, Akiyoshi Hirano2 and Shunichi Yamashita1,4
Keloids are a fibroproliferative disease due to abnormal wound healing process after skin injury. They are
characterized by overproduction of extracellular matrix (ECM) such as collagens. MicroRNAs (miRNAs) are
noncoding small RNAs and negatively regulate protein expression. Several miRNAs that have critical roles in
tissue fibrosis and ECM metabolism have been reported. However, regulation and function of miRNAs in keloid
remain to be explored. The purpose of this study was to identify miRNAs involved in keloid pathogenesis. We
performed miRNA microarray analysis to compare miRNA expression profiles between keloid-derived
fibroblasts (KFs) and normal fibroblasts (NFs). In all, 7 upregulated and 20 downregulated miRNAs were
identified. Among these, we focused on miR-196a, which showed the highest fold change. Overexpression or
knockdown of miR-196a led to a decreased or increased level of secreted type I/III collagens, respectively.
Reporter analysis showed direct binding of miR-196a to the 30 untranslated region (UTR) of COL1A1 and
COL3A1. In conclusion, we demonstrate for the first time that miRNA expression profile is altered in KFs
compared with NFs. Downregulation of miR-196a may be one of the mechanisms by which collagens are highly
deposited in keloid tissues. Our findings suggest that miR-196a could be a new therapeutic target for keloid
lesions.
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INTRODUCTION
Keloids are a benign dermal fibroproliferative disease due to
abnormal wound healing process after skin injury. They are
characterized by overproduction of extracellular matrix
(ECM) and invasiveness beyond the original boundary of
the insult. Excess deposition of ECM such as collagen
(Niessen et al., 1999; Syed et al., 2011) by fibroblasts is
responsible for keloid, but its etiology and mechanism are
still poorly understood. Although keloid is a benign dermal
tumor, its management is one of the most challenging clinical
problems. Keloids do not regress with time, and surgical
excision alone results in a high rate of recurrence. Various
conservative therapies have been attempted, but definite and
effective treatment has not yet been established (Al-Attar
et al., 2006; Seifert and Mrowietz, 2009).
MicroRNAs (miRNAs) are noncoding and single-stranded
small RNAs that negatively regulate gene expression. Mature
miRNA is B22 nucleotides in length; it binds to target
messenger RNA (mRNA) and induces its cleavage or
translational repression depending on the degree of com-
plementarity (Bartel, 2004). miRNAs have critical roles in
many important biological processes, such as cell growth,
proliferation, differentiation, and apoptosis (Esquela-Kerscher
and Slack, 2006). To date, hundreds of miRNAs have been
identified to be dysregulated in various diseased tissues (Lu
et al., 2008), but only a fraction of them have been
functionally characterized.
Recently, some miRNAs have been reported to participate
in fibrosis and ECM metabolism (Jiang et al., 2010; Chau and
Brenner, 2011). The miR-29 family members (miR-29a, miR-
29b, and miR-29c) directly regulate translation of various
ECM mRNAs, such as collagen superfamily (Jiang et al.,
2010; Chau and Brenner, 2011). They are also implicated in
fibroblasts in cardiac fibrosis (van Rooij et al., 2008), stellate
cells in hepatic fibrosis (Ogawa et al., 2010; Roderburg et al.,
2011), and dermal fibroblasts in systemic sclerosis (Maurer
et al., 2010). miR-21 expression is increased selectively in
fibroblasts in failing heart and controls interstitial fibrosis and
cardiac hypertrophy (Thum et al., 2008).
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As a new therapeutic approach for fibrotic disorders,
several miRNA gene therapies have been attempted. In
particular, antagonizing endogenously upregulated miRNA
using antisense strand has been proposed (Brown and
Naldini, 2009). The study of van Rooij et al. (2008) showed
that inhibiting miR-29 using cholesterol-conjugated antisense
strand increased collagen expression in the liver, kidney, and
heart of mice. Another group reported that inhibition of miR-
21 prevented interstitial fibrosis and cardiac hypertrophy in a
mouse model of heart infarction (Thum et al., 2011).
Thus, miRNAs have a number of roles in fibrosis and have
attracted attention as a new target for gene therapy. However,
regulation and function of miRNAs in keloid tissues remain
unknown. In this study, we performed a comprehensive
analysis of miRNA expression in keloid-derived fibroblasts
(KFs) and normal fibroblasts (NFs) using miRNA microarray,
and then explored the function of miR-196a, which showed
the highest fold change in KFs compared with NFs.
RESULTS AND DISCUSSION
Expression profile of miRNAs in KFs
To identify miRNAs specifically regulated in KFs, we first
performed a comprehensive analysis of miRNA expression in
KFs and NFs using miRNA expression microarrays. Each of
the three samples of KFs and NFs was examined for changes
in miRNA expression (Table 1). A total of 27 miRNAs were
identified to be differentially expressed in KFs compared with
NFs (unpaired t-test, Po0.05): of these, 7 miRNAs were
overexpressed and 20 were underexpressed (Table 2). Among
these miRNAs, miRNA-142-3p and miR-196a showed the
highest fold change (miR-142-3p: 9.856-fold and miR-196a:
0.093-fold in KFs compared with NFs). We then focused on
these two miRNAs in the following analysis.
Comparative analysis of the miRNA expression at
passages 0 and 2
Change of gene expressions and growth factor kinetics due to
passage and/or long-time culture has become an important
problem in in vitro research using primary fibroblasts (Yuan
et al., 1996; Hirth et al., 2002). Therefore, we first compared
the expression of those miRNAs in primary fibroblasts at
passage 0 with that at passage 2 by TaqMan real-time reverse
transcriptase–PCR (RT-PCR) assay. Surprisingly, the apparent
difference in miR-142-3p expression at passage 0 was
completely lost at passage 2 (Figure 1a). In contrast, the
difference in miR-196a tended to be expanded after passage
Table 1. The profile of each sample for primary culture
Sex Age (years) Biopsy site
Duration of the
lesion (years) Etiology Previous treatment
Keloid
KF 11 Female 22 Chest 10 Acne Topical corticosteroid, oral administration of tranilast
KF 21 Female 20 Chest 5 Acne Topical corticosteroid
KF 31 Female 15 Shoulder 7 Blister Topical corticosteroid
KF 4 Female 22 Shoulder 10 Unknown Topical corticosteroid, oral administration of tranilast
KF 5 Male 39 Shoulder 20 After ope. Resection and electron beam
KF 6 Male 78 Chest 11 After ope. —
KF 7 Male 38 Chest 20 Acne —
KF 8 Male 16 Shoulder 2 Blister —
KF 9 Male 63 Chest 3 After ope. Topical corticosteroid, oral administration of tranilast
Normal
NF 11 Female 16 Chest — — —
NF 21 Male 82 Thigh — — —
NF 31 Female 36 Thigh — — —
NF 4 Male 75 Chest — — —
NF 5 Male 62 Abdomen — — —
NF 6 Male 73 Palpebra — — —
NF 7 Male 54 Thigh — — —
NF 8 Female 60 Abdomen — — —
NF 9 Female 62 Abdomen — — —
Abbreviations: KF, keloid-derived fibroblast; NF, normal fibroblast; ope., operation.
1Samples used for Agilent miRNA microarray.
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2 (Figure 1b). These data suggest that miRNA expression
could be rapidly altered during early passages. In general,
primary fibroblasts with low passage number are used to
compare gene expression to avoid loss of characteristics
(Feghali and Wright, 1999; Seifert et al., 2008; Smith et al.,
2008). It has been reported that collagen gene expression
changed gradually during passages 0–3 in primary KFs (Syed
et al., 2011). Similarly, the expression pattern of integrin
collagen receptors changed in KFs at successive passages
0–4 (Szulgit et al., 2002). Similarly, the effect of passage
and milieu alteration may affect miRNA expression in KFs.
According to our results (Figure 1), the degree of change
seems to be dependent on each individual miRNA, suggest-
ing that careful analysis is required in experiment to measure
the miRNA expression level in primary KFs. Hence, KFs and
NFs at passage 0 were used in the following experiments.
Validation of the miRNA expression by real-time RT-PCR
To validate the microarray data, we also performed the
TaqMan real-time RT-PCR assay for miR-142-3p and miR-
196a in KFs and NFs using nine samples each (Table 1). As
shown in Figure 2, miR-142-3p was overexpressed (Figure 2a)
and miR-196a was underexpressed (Figure 2b) in KFs
compared with NFs, and these differences were statistically
significant. Of the nine keloid samples, KF1 and KF4 were
obtained from different sites, chest and shoulder, in the same
patient. Six were caused by minor wounds such as acne and
scratch, and three were caused by surgical operations: lung
cancer, coronary artery bypass grafting, and recurrence of
keloid resected 20 years ago (Table 1). Six cases had previous
treatments such as topical corticosteroid and oral adminis-
tration of tranilast, but they were ineffective (Table 1). There
seems to be no correlation between the miRNA expression
level and clinical features. These data indicate that we
successfully confirmed the differential expressions of miR-
142-3p and miR-196a in KFs and NFs.
In silico identification of possible target genes
To explore the mechanisms by which these miRNAs
contribute to keloid pathogenesis, three web-based data-
bases, miRanda (Betel et al., 2008), TargetScan (Lewis et al.,
Table 2. Fold change of miRNA expression
miRNA Fold change (KF/NF)
hsa-miR-142-3p 9.856
hsa-miR-1249 4.068
hsa-miR-136 3.978
hsa-miR-376a* 2.464
hsa-miR-140-5p 1.968
hsa-miR-193a-3p 1.933
hsa-miR-1234 1.333
hsa-miR-23a 0.634
hsa-miR-574-3p 0.628
hsa-let-7d 0.600
hsa-miR-331-3p 0.578
hsa-miR-24 0.553
hsa-let-7a 0.545
hsa-miR-30e* 0.543
hsa-miR-93 0.541
hsa-let-7f 0.540
hsa-miR-98 0.508
hsa-miR-31* 0.433
hsa-miR-31 0.425
hsa-miR-224 0.373
hsa-miR-30a* 0.362
hsa-miR-769-5p 0.331
hsa-miR-595 0.290
hsa-miR-196b 0.246
hsa-miR-452 0.188
hsa-miR-182 0.169
hsa-miR-196a 0.093
Abbreviations: KF, keloid-derived fibroblast; miRNA, microRNA; NF,
normal fibroblast.
*Star form.
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Figure 1. The microRNA (miRNA) expression kinetics in different passages
of keloid-derived fibroblasts (KFs) and normal fibroblasts (NFs). TaqMan
real-time quantitative reverse transcriptase–PCR (RT-PCR) assay was
performed for miR-142-3p and miR-196a in KFs and NFs at passages 0 and 2
using four samples each. (a) miR-142-3p expression kinetics. (b) miR-196a
expression kinetics. The difference between passages 0 and 2 was examined
for statistical significance with paired t-test (*P¼ 0.0245), and the difference
between KFs and NFs was examined with the Mann–Whitney test (**Po0.03).
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Figure 2. TaqMan RT-PCR for miR-142-3p and miR-196a in keloid-derived
fibroblasts (KFs) and normal fibroblasts (NFs) at passage 0 using nine samples
each. (a) miR-142-3p was overexpressed (*P¼0.0005) and (b) miR-196a was
underexpressed (*P¼0.0056) in KFs compared with NFs. The P-values were
obtained by the Mann–Whitney test. Horizontal bar shows median. miRNA,
microRNA.
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2005), and PicTar (Krek et al., 2005), were used to search for
possible target mRNAs of these miRNAs. With regard to
targets of miR142-3p, 2,634 genes in miRanda, 250 genes in
TargetScan, and 200 genes in PicTar were predicted. Among
the three databases, 70 genes were commonly shared
(Supplementary Figure S1 online) and are listed in Supple-
mentary Table S1 online. Correspondingly, 47 genes were
shared as targets of miR-196a (Supplementary Table S2
online): 2,783 genes in miRanda, 180 genes in TargetScan,
and 162 genes in PicTar (Supplementary Figure S1 online).
Collagen genes as a target of miR-196a
The miRNAs were initially proposed to mediate translational
repression of their target mRNAs. However, it has been
recently demonstrated that this is often accompanied by a
decrease in mRNA abundance itself (Baek et al., 2008;
Selbach et al., 2008). We therefore searched for target genes
of miR-142-3p using real-time RT-PCR for mRNA; among the
candidate genes, we examined ADCY9, BCLAF1, CFL2,
COL24A1, HMGA2, and ROCK2, which are implicated in
collagen synthesis, apoptosis, actin filaments, collagen,
transforming growth factor-b signaling, and Rho-actin signal-
ing, respectively. Unfortunately, we did not identify repro-
ducible differences in any of these candidates between nine
KF and nine NF samples (data not shown). Presumably, these
genes are regulated by a number of different pathways,
and miR-142-3p is probably not a major effector in dermal
fibroblasts.
Among the predicted target genes of miR-196a, we
focused on collagens (COL1A1, COL1A2, and COL3A1),
because one of the major findings in keloid pathology is
increased ECM deposition, and collagen family is a dominant
component of ECM (Al-Attar et al., 2006). The expression of
some of collagen mRNAs is increased in KFs (Shih and Bayat,
2010), and type I and III collagen proteins are increased in
keloid (Ala-Kokko et al., 1987; Syed et al., 2011). We
confirmed the increased level of COL1A1, COL1A2, and
COL3A1 mRNAs in our samples (Supplementary Figure S2
online).
Indeed, COL1A1, COL1A2, and COL3A1 have potential
miR-196a target site in their 30 untranslated region (UTR), and
the complementarity between the target sites and the miR-
196a seed region (2–8 nucleotides of the 50-end of miR-196a)
is completely matched (Supplementary Figure S3 online). The
complementarity between the seed region of miRNA and
30UTR of mRNAs is the most important determinant for target
specificity (Bartel, 2009), and miRNA-mediated translational
repression often depends on perfect or near-perfect base
pairing of a seed region to its target (Doench and Sharp,
2004). Therefore, type I and III collagens are strong
candidates that are regulated by miR-196a.
Effect of miR-196a on the expression of collagens
To determine the biological function of miR-196a, we used
predesigned and functionally tested Pre-miR miRNA Pre-
cursor Molecule (Pre-miR-196a) and Anti-miR miRNA
Inhibitor (Anti-miR-196a) to overexpress and knockdown
miR-196a, respectively. We first assessed transfection
efficiency using FAM-labeled Pre-miR and Anti-miR
Scrambled Negative Control (Scrambled) with a fluorescence
microscope, and it was almost 100% in our hands (data not
shown). We also confirmed a robust increase of the miR-196a
level following Pre-miR-196a transfection (Figure 3a) by
TaqMan real-time RT-PCR assay. We then transfected NFs
and KFs with Pre-miR-196a or Anti-miR-196a, and the
protein levels of collagens secreted into supernatants were
measured by western blot analysis. The secretion of type I
and III collagens into culture media was reduced in KFs and
NFs transfected with Pre-miR-196a (Figure 3b). On the other
hand, knockdown of miR-196a by Anti-miR-196a increased
the expression of these collagens (Figure 3b). These results
suggest that miR-196a regulates the secretion of collagens I
and III in fibroblasts of dermal tissue.
Luciferase reporter assay
To further investigate whether miR-196a directly regulates
the expression of type I and III collagens, we generated
luciferase reporter plasmids containing the 30UTR of the
COL1A1 or COL3A1 gene (pmirGLO-COL1A1-30UTR and
pmirGLO-COL3A1-30UTR). First, we transfected these plas-
mids into NFs and KFs and measured luciferase activity. As
shown in Figure 3c, the luciferase activity in KFs was
significantly higher than that in NFs. It may reflect the
difference of the miR-196a expression between KFs and
NFs. Next, NFs were transfected with the reporter plasmids
together with Pre-miR-196a or Anti-miR-196a. As shown in
Figure 3d, co-transfection with Pre-miR-196a reduced both
luciferase activities driven from the reporter plasmids
carrying the COL1A1 and COL3A1 30UTR. Moreover, Anti-
miR-196a increased the luciferase activities as compared
with the scramble (Figure 3e). These findings suggest that
miR-196a directly regulates the expression of collagens I and
III through targeting the 30UTRs of the COL1A1 and COL3A1
genes in fibroblasts.
CpG island methylation of the miR-196a promoters
It has been recently reported that some of the disease-
associated miRNAs are silenced by aberrant DNA methyla-
tion of their promoter CpG islands (Lujambio et al., 2007;
Kozaki et al., 2008; Bandres et al., 2009; Tsai et al.,
2010). To determine whether promoter methylation is
responsible for miR-196a underexpression in KFs, we used
a methylation-specific PCR method. Mature miR-196a
derives from two pri-miRNAs: pri-miR-196a-1 (genomic region,
chr17:46,709,852–46,709,921) and pri-miR-196a-2 (geno-
mic region, chr12:54,385,522–54,385,631); genomic regions
are based on the NCBI (National Center for Biotechnology
Information) database (http://www.ncbi.nlm.nih.gov/). We
then examined both promoter regions of these two pri-
miRNAs. As previous studies have indicated that most human
miRNA promoters are located approximately 1,000 bp
upstream of mature miRNA (Zhou et al., 2007; Saini et al.,
2008), primers designed within CpG island that are located
on the putative promoter region were used (Hoffman et al.,
2009; Suzuki et al., 2011). As shown in Figure 4a,
unmethylated promoters were dominant for pri-miR-196a-1.
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On the other hand, methylation was remarkable for pri-miR-
196a-2 (Figure 4b). However, there were no differences in the
level of methylation status between KFs and NFs in both loci
(Figure 4a and b). These data suggest that downregulation of
the miR-196a expression in KFs is not due to epigenetic
regulation by aberrant methylation of their promoter regions.
Other upstream unknown factors may be involved in this
regulation.
In summary, the expression profiles of miRNA between
KFs and NFs were apparently distinct. As it has been
demonstrated that each individual miRNA could have
hundreds of mRNA targets, miRNAs that are differentially
regulated in KFs may have a variety of roles in keloid
pathogenesis. miR-196a displayed the highest altered expres-
sion in KFs compared with NFs and regulated the expression
of type I and III collagens, whose deposition is a major
manifestation in keloid pathology. The mechanisms of the
reduced expression of miRNA-196a still remain to be
elucidated; however, miR-196a could be an attractive
therapeutic target, as there have been attempts trying topical
administration of RNA-based drugs (Ritprajak et al., 2008;
Takanashi et al., 2009; Bak and Mikkelsen, 2010).
MATERIALS AND METHODS
Tissue samples
Nine keloid tissue samples were obtained from eight different
Japanese patients at the time of surgery, and diagnosis was
confirmed by routine pathological examination. Normal skin tissue
samples were obtained from nine different Japanese volunteers. All
experiments were conducted after obtaining approval of the ethics
committee of Nagasaki University Hospital, and in accordance with
the Declaration of Helsinki Principles. Written informed consent was
obtained from each individual. The sample profiles are summarized
in Table 1.
*P <0.0001
3x105 Pro I
KF NF KF NF MW
(kDa)
160
160
220
Processed I
Pro III
Processed III
Fibronectin
Pre-miR-196a –
– – – –+
– – –+ +
+
–
– – – –+
– – –+ +
+
Scramble
Scramble
Anti-miR-196a
*
2x105
1x105
0
4 3
1.2 1.2 3
2
1
0
3
2
1
0Scra
m
ble
Pre-m
iR
-196a
Scra
m
ble
Pre-m
iR
-196a
Scra
m
ble
Anti-m
iR
-196a
Scra
m
ble
Anti-m
iR
-196a
0.4
0
0.8
0.4
0
0.8
2
1
0
COL1A1 COL3A1 COL1A1 COL3A1 COL1A1 COL3A1
*P =0.0315 *P =0.005 *P =0.0043 *P =0.0286 *P =0.007 *P =0.0159
* *
* *
*
*
3
2
1
0
KF NF KF NF
R
el
at
ive
 lu
ci
fe
ra
se
 a
ct
iv
ity
R
el
at
ive
 lu
ci
fe
ra
se
 a
ct
iv
ity
R
el
at
ive
 lu
ci
fe
ra
se
 a
ct
iv
ity
Control
Scra
m
ble
Pre-m
iR
 - 196a
R
el
at
ive
 m
iR
N
A 
ex
pr
es
sio
n
Figure 3. Functional analysis of miR-196a. (a) After transfection of Pre-miR-196a, the level of miR-196a was confirmed by TaqMan real-time quantitative
reverse transcriptase–PCR (RT-PCR) assay. *Po0.001 versus others. The P-value was obtained by one-way analysis of variance (ANOVA) followed by Tukey’s
post test. (b) Indicated cells were transfected with Pre-miR-196a, Anti-miR-196a, or scrambled control. At 72 hours after the transfection, cultured media
(extracellular matrix (ECM)) were analyzed by western blot analysis. Fibronectin was used as a loading control. The migration positions of indicated procollagens
and molecular weight (MW) marker are shown. Similar results were obtained using three different normal fibroblast (NF)/keloid-derived fibroblast (KF) lines. Pro
I, procollagen a1(I)/a2(I); Processed I, pC/pN-collagen a1(I)/a2(I); Pro III, procollagen a1(III); Processed III, pC/pN-collagen a1(III). (c–e) Activity of luciferase
reporter containing the 30 untranslated region (UTR) regions of COL1A1 or COL3A1. (c) Relative luciferase activity in KFs versus NFs using nine samples each.
Cells were transfected with pmirGLO-COL1A1-30UTR or pmirGLO-COL3A1-30UTR and incubated for 24 hours. Luciferase activity was measured as described
in the Materials and Methods. Difference between KFs and NFs was examined for statistical significance using the Mann–Whitney test. Horizontal bar shows
median. (d, e) NFs were co-transfected with the reporter plasmids and (d) Pre-miR-196a or (e) Anti-miR-196a. At 24 hours after the transfection, luciferase
activity was measured. Bar shows mean±SD of three independent experiments. The P-values were obtained by Mann–Whitney test.
www.jidonline.org 1601
K Kashiyama et al.
miR-196a and Collagens I and III in Keloids
Cell culture
Primary culture of dermal fibroblasts was established as previously
described (Arakawa et al., 1990). Explants were maintained in
DMEM supplemented with 10% heat-inactivated fetal bovine serum
and 1% (w/v) penicillin/streptomycin in 5% CO2 humidified
atmosphere at 37 1C. Fibroblasts obtained at the first culture for
2 weeks (at passage 0) were used in this study, except as indicated
otherwise.
miRNA microarray
Total RNAs were extracted from KFs and NFs using an miRNeasy
mini kit (QIAGEN, Tokyo, Japan) according to the manufacturer’s
instruction. A measure of 500 ng of the total RNAs was subjected to
an Agilent miRNA microarray analysis service (Hokkaido System
Science, Sapporo, Japan). Data analysis was done with the Gene-
Spring GX software (Agilent Technology Japan, Tokyo, Japan). The
array contained probes for 866 human and 89 viral miRNAs. Probes
with ‘‘present call’’ flag in at least one sample in both groups were
used for further data analyses (27 probes). Differences between
groups were examined for statistical significance with unpaired
t-test. P-value not exceeding 0.05 was considered statistically
significant.
Real-time RT-PCR for miRNA
The quantitative real-time RT-PCR for miRNA was performed using
TaqMan MicroRNA Assays (Applied Biosystems, Life Technologies
Japan, Tokyo, Japan). Briefly, 10 ng of total RNA were reverse
transcribed using a specific looped RT primer for each miRNA using
a corresponding TaqMan MicroRNA Reverse Transcription kit
(Applied Biosystems). The following amplification was performed
using a corresponding TaqMan MicroRNA Assay Mix, TaqMan
Universal PCR Master Mix, and No AmpErase UNG (Applied
Biosystems) in a Thermal Cycler Dice Real-time system (TaKaRa Bio,
Ohtsu, Japan). RNU6B was used as an internal control. The cycle
threshold value, which was determined using second derivative, was
used to calculate the normalized expression of the indicated
miRNAs using the Q-Gene software (Muller et al., 2002).
Real-time RT-PCR for mRNA
Total RNA was extracted using ISOGEN reagent (NIPPON GENE,
Tokyo, Japan) according to the manufacturer’s instruction. A
measure of 1mg of total RNA was reverse transcribed using a
High-capacity RNA-to-cDNA kit (Applied Biosystems). The follow-
ing PCR amplification was carried out in a Thermal Cycler Dice
Real-time system using SYBR Premix Ex Taq II (TaKaRa Bio). For
each sample, the relative mRNA level was normalized by ribosomal
RNA 18S. The following primer pairs were used: COL1A1 sense,
50-CGAAGACATCCCACCAATCAC-30 and anti-sense, 50-GATCG
CACAACACCTTGCC-30; COL1A2 sense, 50-TGCCTAGCAACAT
GCCAATC-30 and anti-sense, 50-TCCTCTATCTCCGGCTGGG-30;
COL3A1 sense, 50-TCCCACTATTATTTTGGCACAACA-30 and anti-
sense, 50-TCATCGCAGAGAACGACGGATCC-30; 18S sense, 50-
GTAACCCGTTGAACCCCATT-30 and anti-sense, 50-CCATCCAATC
GGTAGTAGCG-30.
Western blot
To obtain secreted ECM proteins, culture media were collected and
filtered with a 0.22 mm filter (MillexGV, Millipore, Bedford, MA).
Protein concentration was determined with a Bichinonic Acid Assay
kit (Sigma-Aldrich Japan, Tokyo, Japan). Equal amount of proteins
(15 mg) were mixed in sample buffer containing 0.125M Tris-HCl
(pH6.8), 30% glycerol, 35 mM SDS, 60 mM dithiothreitol, and
bromphenol blue. After heating for 3minutes at 99 1C, the proteins
were resolved by SDS-PAGE and transferred onto polyvinylidene
difluoride membrane (Millipore) by semidry blotting. After incuba-
tion with appropriate primary antibody, the antigen–antibody
complex was visualized using horseradish peroxidase–conjugated
secondary antibody and the Chemi-Lumi One system (Nacalai
Tesque, Kyoto, Japan). To enhance sensitivity, Can Get Signal
reagent (TOYOBO, Osaka, Japan) was used. Detection was
performed using a LAS3000 imaging system (FUJI film, Tokyo,
Japan). Antibodies were obtained from the following sources: anti-
fibronectin polyclonal from Santa Cruz Biotechnology (Santa Cruz,
CA); anti-collagen type I polyclonal and anti-collagen type III
polyclonal from Rockland Immunochemicals (Gilbertsville, PA); and
horseradish peroxidase–conjugated secondary anti-rabbit/mouse IgG
from Cell Signaling Technology (Beverly, MA).
Transfection of pre-miR/anti-miR-196a
Cells were transfected with Pre-miR miRNA Precursor Molecule for
miR-196a (Pre-miR-196a), Anti-miR miRNA Inhibitor for miR-196a
(Anti-miR-196a), FAM-labeled Pre-miR Scrambled Negative Control
#1, or Anti-miR Scrambled Negative Control #1 using Lipofectamine
2000 (Invitrogen, Life Technologies Japan, Tokyo, Japan) at a final
concentration of 50 nM. All the above functional molecules were
purchased from Applied Biosystems. Transfection efficiency was
assessed using a fluorescence microscopy DM6000B (Leica Micro-
systems, Tokyo, Japan).
Luciferase reporter assay
The 30UTRs containing the putative miRNA target regions of the
COL1A1 and COL3A1 genes were amplified by PCR using fibroblast
genomic DNA as a template. The following primer pairs were used:
COL1A1 sense, 50-ATTCCACTCGAGCTCCCTCCATCCCAACCTG
GC-30 and anti-sense, 50-GCCATAGTCGACATGTTTGGGTCAT
TTCCACATGCTT-30; COL3A1 sense, 50-ACAGCTCTCGAGACCA
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Figure 4. Methylation status of the miR-196a promoters in keloid-derived
fibroblasts (KFs) and normal fibroblasts (NFs). Genomic DNA was extracted
and analyzed by methylation-specific PCR. (a) miR-196a-1. (b) miR-196a-2.
Methylated control, unmethylated control, and template-free negative control
were also included. M, methylated; U, unmethylated.
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AACTCTATCTGAAATCCCAACA-30 and anti-sense, 50-AGAATCGT
CGACGAATTTTAATATGATATTTTATTATGGGTG-30. The sense
and anti-sense primers carry the XhoI and SalI sites at their 50-ends,
respectively. The obtained DNA fragments were inserted into
pmirGLO plasmid (Promega, Tokyo, Japan) to generate pmirGLO-
COL1A1-30UTR and pmirGLO-COL3A1-30UTR. Fibroblasts were
seeded on 96-well plates in DMEM supplemented with 10% fetal
bovine serum at a density of 1 104 cells per well, and they were
transfected with 200 ng of the reporter plasmid together with Pre-
miR-196a, Anti-miR-196a, or Scrambled control. The Dual-Glo
Luciferase Assay System (Promega) and a TD-20/20 luminometer
(Turner Designs, Sunnyvale, CA) were used to analyze luciferase
expression according to the manufacturer’s protocol. Firefly lucifer-
ase activity was measured and normalized to Renilla luciferase
activity to adjust for variations in transfection efficiency among
experiments.
Methylation-specific PCR
DNA methylation patterns in the promoter region of the miR-196a-1
and miR-196a-2 genes were analyzed by methylation-specific PCR
as previously described, with minor modifications (Esteller et al.,
1999; Umetani et al., 2005). Briefly, genomic DNA was isolated
from cells using a QIAamp DNA Mini kit (QIAGEN). Bisulfite
conversion was then carried out using an EpiTect Bisulfite kit
(QIAGEN). The subsequent PCR was done using ExTaq HS (TaKaRa
Bio). The primer sequences are as described previously for miR-
196a-1 (Suzuki et al., 2011) and miR-196a-2 (Hoffman et al., 2009).
The thermal profile was as follows: 95 1C for 3minutes, 40 cycles of
94 1C for 30 seconds, 61 1C (196a-1) or 49 1C (196a-2) for
30 seconds, and 72 1C for 10 seconds. DNA from T98G (glioblastoma
cell line) was treated with SssI methyltransferase (New England
Biolabs, Beverly, MA) and used as a methylated control. DNA from
T98G was amplified using a GenomiPhi V2 kit (GE Healthcare Bio-
sciences, Piscataway, NJ) and used as an unmethylated control. The
PCR product was loaded onto a 3% agarose gel, stained with
ethidium bromide, and visualized under UV illumination with a Bio-
Doc-It (UVP, Cambridge, UK).
Statistical analysis
Difference between two related groups was examined for statistical
significance with paired t-test, and two independent groups were
examined with Mann–Whitney test. For more than two groups, one-
way analysis of variance followed by Tukey’s posttest was used.
P-value not exceeding 0.05 was considered statistically significant.
Data were analyzed with the PRISM software, version 4 (GraphPad
Software, La Jolla, CA).
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